Company Filing History:
Years Active: 2012-2023
Title: Innovations in Cancer Treatment by Kinfe Ken Redda
Introduction
Kinfe Ken Redda is a prominent inventor based in Tallahassee, Florida. He has made significant contributions to the field of cancer research, particularly in developing novel anti-cancer agents. With a total of seven patents to his name, his work focuses on innovative treatments for triple negative breast cancer.
Latest Patents
One of his latest patents is titled "Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancer." This patent presents novel compositions and methods for treating triple negative breast cancer. The compound 4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide has demonstrated the ability to downregulate the expression of several genes associated with triple negative breast cancer, including amphiregulin, epiregulin, and cyclooxygenase-2. Additionally, it has been shown to inhibit the oncostatin M signaling pathway, which is crucial in cancer progression.
Another significant patent is "Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents." This patent discloses N-substituted tetrahydroisoquinoline ethylbenzamide compounds with modifications on the phenyl rings. These derivatives have shown anti-proliferative activity against cancer cells, particularly those originating in breast tissue. Notably, the novel compounds exhibit IC values against breast cancer cells that are 6- to 10-fold less than the IC of Tamoxifen, highlighting their potential as effective cancer treatments.
Career Highlights
Kinfe Ken Redda is affiliated with Florida A&M University, where he continues to advance his research in cancer therapeutics. His innovative work has positioned him as a key figure in the development of new treatment options for challenging cancer types.
Collaborations
He collaborates with esteemed colleagues, including Madhavi Gangapuram and Karam F A Soliman, to further enhance the impact of his research. Their combined expertise contributes to the advancement of cancer treatment methodologies.
Conclusion
Kinfe Ken Redda's contributions to cancer research through his innovative patents demonstrate his commitment to improving treatment options for patients with triple negative breast cancer. His work not only showcases his inventive spirit but also holds promise for future advancements in oncology.